Currently, interventional therapy has become an important tool in the treatment of patients with coronary heart disease, and more and more patients with coronary heart disease are receiving this treatment. I have been engaged in cardiovascular disease and coronary intervention for more than 10 years, and I would like to share some of my experiences and insights with patients. First of all, patients with coronary artery disease who undergo interventional therapy do so as a last resort, such as most patients with acute myocardial infarction (acute phase) and unstable angina. Interventional treatment can indeed relieve symptoms and improve the prognosis of patients in the near future. However, interventional therapy is only one aspect of coronary artery disease treatment, or one point of the total treatment. If you don’t pay much attention to your lifestyle, you will have to change your ways after the intervention, such as quitting smoking, limiting alcohol, eating a reasonable diet (more vegetables and fruits), exercising more, having a calm mind and regular rest, etc., because you have paid a heavy price for your body. Interventional treatment is not the end of coronary heart disease treatment, but exactly the beginning of treatment for most patients. Having a healthy lifestyle is one of the most important aspects of treatment for patients with coronary artery disease, so to speak, from the source. In addition, unhealthy lifestyle is also prone to hypertension, diabetes, and dyslipidemia, which are reversible risk factors for coronary heart disease, and the control of these risk factors is also closely related to the improvement of healthy lifestyle. Currently, some international studies also support this view. Second, patients after interventional procedures should be intensified with pharmacological therapy. On the one hand, they should be intensively treated with dual antiplatelet therapy for at least one year or longer, and then receive an antiplatelet drug for life; on the other hand, they should reasonably apply drug therapy to control related risk factors: for example, the selection of antihypertensive drugs, in addition to ensuring the efficacy of smooth blood pressure lowering, should also focus on the improvement and protection of organ function, and the selection of hypoglycemic drugs should take into account liver and kidney function to avoid the occurrence of hypoglycemia. It is best to apply insulin therapy, statin {lipid therapy should be used for a longer period of time, and must ensure that the LDL standard, if necessary, combined with cholesterol absorption inhibitors to control . Of course, the choice of these drugs should be based on evidence-based medicine. It is also important to see a relatively regular physician to review blood-related indicators and other ancillary tests to evaluate the occurrence of restenosis or new lesion development after interventional therapy.